Are endocan plasma levels altered in preeclampsia?

• Autor(a) principal: Ana Cristina dos Santos Lopes
• Data de Publicação: 2021
• Outros Autores: Suellen Rodrigues Martins, Luci Maria SantAna Dusse, Melina de Barros Pinheiro, Patrícia Nessralla Alpoim
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.1055/s-0041-1728661; http://hdl.handle.net/1843/57395
• topic: Humans; Female; Pregnancy; Pre-eclampsia; Proteoglycans; Biomarkers; Case-control studies; Gravidez; Pré-eclâmpsia; Proteoglicanas; Biomarcadores; Estudos de casos e controles

Our research group has been studying preeclampsia (PE) for over a decade aiming to detect possible blood biomarkers of hemostasis, inflammation, and endothelial dysfunction that could be useful for the diagnosis of PE. Until today, only the onset of hypertension (≥ 140 mmHg systolic or ≥ 90 mmHg diastolic) on or after 20 weeks of gestation in association or not with proteinuria and/or evidences of multisystem impairment (such as renal, liver and neurological dysfunctions) is an acceptable criterion to establish the diagnosis of this gestational disease. It is important to emphasize that PE affects between 2 and 8% of all pregnancies worldwide, an early diagnosis of the disease, before the occurrence of systematic impairment, is still not available, which motivates our arduous search for laboratory markers of PE. Endocan is a biochemical marker of endothelial dysfunction that is potentially associated with immunoinflammatory response. Previous data of our group showed that endothelial dysfunction and inflammation are important features in PE. Aiming to determine if endocan plasma levels could be useful for determining PE predisposition and/or development, we investigate its levels in preeclamptic and normotensive pregnant women from the southeastern state of Minas Gerais, Brazil.